Researchers update clinical practice guidelines for how to prevent and monitor hepatitis B virus reactivation.

The American Gastroenterological Association (AGA) has unveiled an updated clinical practice guideline in Gastroenterology addressing the prevention and management of hepatitis B virus reactivation ...

In resource-limited countries, tenofovir, a potent and well-tolerated antiviral drug with dual activity against HBV and HIV, is available at generic prices (€72/patient/year), but it is still ...

A recent article in the journal Nature Communications describes the structural basis of mimicked HBV/HDV viral peptide drug interaction with its receptor NTCP. HBV, an enveloped DNA virus ...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.

persistence of HBsAg for more than 6 months refers to chronic HBV infection. Anti-HBs is a neutralizing antibody and its presence suggests the recovery from hepatitis B and confers a long-term ...

GSK has set its sights on dominance of the market for hepatitis B virus (HBV) therapeutics, licensing an antisense oligonucleotide drug from Arrowhead Pharma and Johnson & Johnson that had been ...

In a new clinical practice guideline, the AGA provided evidence-based recommendations for either antiviral prophylaxis or continued surveillance to manage hepatitis B virus reactivation in patients ...

GigaGen, a subsidiary of Grifols, has commenced a Phase I dose escalation trial, with the first patient receiving a dose of GIGA-2339, a recombinant polyclonal drug candidate aimed at treating ...